IVF earnings analysis
What we found in IVF's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted 10-Q does not provide current-period revenue, margins, EPS, cash flow, balance-sheet figures, segment results, or quantitative guidance, so operating trends cannot be assessed from the filing text supplied. The principal disclosure is negative: management concluded that disclosure controls and internal control over financial reporting were not effective as of June 30, 2026 due to 2 material weaknesses. Remediation is underway, including added accounting resources and planned improvements to segregation of duties, documentation, training, and review procedures.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Control remediation underway
- Management stated that disclosure controls and procedures were not effective as of June 30, 2026, and described an ongoing remediation program.
- Accounting resources being expanded
- The company added accounting resources and plans additional personnel, training, documentation, supervision, and more frequent financial-statement reviews to address the deficiencies as of June 30, 2026.
- No material legal proceedings
- The company reported that it was not currently subject to any material legal proceedings as of August 14, 2026.
- No unregistered equity sales
- The filing reported no unregistered sales of equity securities during the quarter ended June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material weaknesses in internal controls
- As of June 30, 2026, internal control over financial reporting was not effective because of 2 material weaknesses: limited segregation of duties and insufficient accounting resources for complex transactions.
- Potential financial misstatements
- The identified control deficiencies could result in material misstatements of significant accounts and disclosures that are not prevented or detected, according to the filing dated August 14, 2026.
- Limited risk-factor disclosure
- Item 1A states that smaller reporting companies are not required to provide risk-factor disclosures, so this 10-Q does not provide a detailed update to evaluate changes versus the prior filing as of August 14, 2026.
What they said about what is next.
No quantitative revenue or EPS outlook was provided in the filing; the extracted filing is focused on controls and other information rather than operating results.
The filing reads worse than the one before it.
What came before.
- 10-Q · June 22, 2026
- INVO Fertility, Inc. reported a revenue of $1.583 million for Q4 2026, falling short of estimates by 17.9%. The company posted an EPS of -40.4, which was significantly below the anticipated -22.0. Despite an overall…
- 10-K · June 12, 2026
- INVO Fertility, Inc. reported fiscal year 2025 revenue of $6,841,250, a 5% increase from the previous year, despite an increase in operating losses. The company aims to expand clinic operations and fortify its financial…
- 10-K · June 2, 2026
- INVO Fertility (IVF) is focused on expanding access to ART care by acquiring and operating fertility clinics, including those utilizing its proprietary INVOcell device. Despite a notable acquisition strategy, the…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing IVF makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever